The axial spondyloarthritis (axSpA) treatment market is primarily driven by the rising disease prevalence of the condition globally. Axial spondyloarthritis (axSpA) refers to a group of inflammatory diseases that causes pain and stiffness in the spine and sacroiliac joints. The major symptoms include chronic back pain, restricted range of spinal motion, and inflammation. The condition is often confused with rheumatoid arthritis and low back pain since both exhibit similar symptoms. The mainstay treatment involves nonsteroidal anti-inflammatory drugs (NSAIDS), physiotherapy, and biologics.

The Global Axial Spondyloarthritis (axSpA) Market is estimated to be valued at US$ 6.02 Billion in 2024 and is expected to exhibit a CAGR of 7.5% over the forecast period 2024-2031.



Key Takeaways



Key players operating in the axial spondyloarthritis (axSpA) treatment market are AbbVie Inc., Novartis AG, Pfizer Inc., UCB Pharma, and Eli Lilly and Company. These players are focusing on developing innovative biologics for effective management of the condition.



The key opportunities in the market include a large patient pool suffering from axial spondyloarthritis globally, increasing awareness regarding disease diagnosis and management, and robust product pipelines. Several biologics are anticipated to be launched during the forecast period.



The major companies are expanding their geographical presence across countries worldwide. For instance, AbbVie Inc. launched axSpA treatment, Rinvoq, in markets of Europe in 2022 to strengthen its global leadership. Meanwhile, Novartis AG collaborated with global research institutes to expedite clinical trials of candidate drugs.



Market Drivers

Growing disease prevalence worldwide due to improved diagnostic capabilities and changing lifestyle habits is a major market driver. As per estimates, over 2 million people across the globe suffer from axial spondyloarthritis currently.



Another key driver is the rising popularity of biologics over conventional NSAIDs owing to their target specific mechanism and ability to induce clinical remission. Biologics are fast becoming the first line treatment option in severe cases.



Market Restraints

High costs associated with biologics hamper their widespread adoption in developing nations. The yearly cost of biologics ranges from US$ 30,000 to 50,000, making them unaffordable for many patients.



Stringent regulations for drug approvals also act as a market challenge. Biologics require extensive clinical trials data to prove their safety and efficacy profiles before receiving approvals. This lengthens the product launch timelines.

Segment Analysis

The axial spondyloarthritis treatment market is dominated by biologics segment. Axial spondyloarthritis or axSpA is an umbrella term for inflammatory arthritis of the spine and sacroiliac joints which primarily includes non-radiographic axial spondyloarthritis (nr-axSpA) and radiographic axial spondyloarthritis (also known as ankylosing spondylitis or AS). Biologics such as tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of axSpA and are highly effective in reducing signs and symptoms including spinal inflammation and pain. Some key biologics include Humira, Remicade and Enbrel that are prescribed initially in patients who are intolerant or refractory to conventional NSAIDs therapy.



Global Analysis

Regionally, North America is expected to dominate the global axial spondyloarthritis treatment market during the forecast period. Factors such as high diagnosis rates, growing patient awareness levels about available treatment options for axSpA management and reimbursement availability for biologics contribute to its large market share.

Meanwhile, the Asia Pacific region is poised to exhibit the fastest growth rate over next few years led by expanding healthcare infrastructure, rising healthcare spending and increasing focus of key biologics makers on emerging countries through licensing deals and supply agreements. Europe takes the second largest share with majority patients enrolling in early diagnosis programs and specialist-led patient management pathways.

Get more insights on this topic : https://heyjinni.com/read-blog/168006

What Are The Key Data Covered In This Axial Spondyloarthritis (axSpA) Treatment   Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Axial Spondyloarthritis (axSpA) Treatment  's growth between 2024 and 2031.

:- Accurate calculation of the size of the Axial Spondyloarthritis (axSpA) Treatment   and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Axial Spondyloarthritis (axSpA) Treatment   Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Axial Spondyloarthritis (axSpA) Treatment   vendors

Author Bio:

Alice Mutum is a seasoned senior content editor at Coherent Market Insights, leveraging extensive expertise gained from her previous role as a content writer. With seven years in content development, Alice masterfully employs SEO best practices and cutting-edge digital marketing strategies to craft high-ranking, impactful content. As an editor, she meticulously ensures flawless grammar and punctuation, precise data accuracy, and perfect alignment with audience needs in every research report. Alice's dedication to excellence and her strategic approach to content make her an invaluable asset in the world of market insights.

(LinkedIn: www.linkedin.com/in/alice-mutum-3b247b137 )

*Note:

1. Source: Coherent Market Insights, Public sources, Desk research

2. We have leveraged AI tools to mine information and compile it